S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
A small venture capital player becomes a symbol in the fight over corporate diversity policies
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
5 Reasons Why Amprius is About to Take Flight 
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
A small venture capital player becomes a symbol in the fight over corporate diversity policies
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
5 Reasons Why Amprius is About to Take Flight 
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
A small venture capital player becomes a symbol in the fight over corporate diversity policies
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
5 Reasons Why Amprius is About to Take Flight 
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
A small venture capital player becomes a symbol in the fight over corporate diversity policies
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
5 Reasons Why Amprius is About to Take Flight 
NYSEARCA:PBE

Invesco Biotechnology & Genome ETF (PBE) Price, Holdings, & News

$58.48
-0.31 (-0.53%)
(As of 09/20/2023 ET)
Compare
Today's Range
$58.48
$59.11
50-Day Range
$58.39
$64.05
52-Week Range
$56.31
$68.50
Volume
3,845 shs
Average Volume
5,984 shs
Market Capitalization
$232.16 million
Assets Under Management
$231.51 million
Dividend Yield
0.02%
Net Expense Ratio
0.58%

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors. Invesco PowerShares Capital Management LLC acts as the Fund’s investment adviser.

PBE Price History

PBE ETF News Headlines

PBE Offers Exposure to Surging Catalent Stock
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
Invesco Dynamic Biotechnology & Genome ETF (PBE)
PBE Invesco Dynamic Biotechnology & Genome ETF
Virtus LifeSci Biotech Clinical Trls ETF
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
See More Headlines
Receive PBE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Invesco Biotechnology & Genome ETF and its competitors with MarketBeat's FREE daily newsletter.

Fund Details

Issuer
Invesco
Fund Name
Invesco Biotechnology & Genome ETF
Tax Classification
Regulated Investment Company
Current Symbol
NYSEARCA:PBE
Inception Date
6/23/2005
Fund Manager
Peter Hubbard, Michael Jeanette, Pratik Doshi, Tony Seisser

Fund Focus

Asset Class
Equity
Benchmark
Dynamic Biotech & Genome Intellidex Index
Category
Sector
Focus
Health Care
Development Level
Developed Markets
Region
North America
Number of Holdings
31

Fund Statistics

Assets Under Management
$232.83 million
Average Daily Volume
$7,873.40
Discount/Premium
0.00%

Administrator, Advisor and Custodian

Administrator
The Bank of New York Mellon Corporation
Advisor
Invesco Capital Management LLC
Custodian
The Bank of New York Mellon Corporation
Distributor
Invesco Distributors, Inc.
Transfer Agent
The Bank of New York Mellon Corporation
Trustee
N/A
Lead Market Maker
N/A

Options

Optionable
N/A
Short Interest
13,000 shs

Miscellaneous

Beta
0.87
Creation Unit
10,000
Creation Fee
$500.00
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Invesco Biotechnology & Genome ETF Expenses

TypePBEHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFs
Management Fee0.50%0.57%0.53%0.50%0.50%
Other Expenses0.08%0.40%0.52%0.64%0.57%
Total Expense0.58%0.72%0.69%0.74%0.69%
Fee Waiver0.00%-0.51%-0.55%-0.70%-0.59%
Net Expense0.58%0.61%0.59%0.57%0.57%

Invesco Biotechnology & Genome ETF (PBE) Holdings & Exposure

PBE Sector Exposure

PBE Industry Exposure

Key Executives

  • H. Bruce Bond
    Chairman of the Board of Trustee, Chief Executive Officer
  • Bruce T. Duncan
    Chief Financial Officer, Treasurer
  • Kevin R. Gustafson
    Chief Compliance Officer
  • Keith A Ovitt
    Secretary
  • Ronn R. Bagge
    Trustee
  • Marc M Kole
    Trustee
  • D. Mark McMillan
    Trustee
  • Philip M. Nussbaum Mba
    Trustee
  • Donald H. Wilson
    Trustee













PBE ETF - Frequently Asked Questions

How have PBE shares performed in 2023?

Invesco Biotechnology & Genome ETF's stock was trading at $63.4970 at the beginning of 2023. Since then, PBE stock has decreased by 7.9% and is now trading at $58.4775.
View the best growth stocks for 2023 here
.

What does PBE invest in?

Invesco Biotechnology & Genome ETF is a equity fund issued by Invesco. PBE focuses on health care investments and follows the Dynamic Biotech & Genome Intellidex Index. The fund's investments total to approximately $232.83 million assets under management.

What is the management fee for Invesco Biotechnology & Genome ETF?

Invesco Biotechnology & Genome ETF's management fee is 0.50% and has other expenses of 0.08%. The net expense ratio for PBE is 0.58%.

What other stocks do shareholders of Invesco Biotechnology & Genome ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Invesco Biotechnology & Genome ETF investors own include Pfizer (PFE), Intel (INTC), Align Technology (ALGN), Micron Technology (MU), Activision Blizzard (ATVI), DocuSign (DOCU), Inovio Pharmaceuticals (INO), Mastercard (MA), Hello Group (MOMO) and ONEOK (OKE).

What is Invesco Biotechnology & Genome ETF's stock symbol?

Invesco Biotechnology & Genome ETF trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "PBE."

Who are Invesco Biotechnology & Genome ETF's major shareholders?

Invesco Biotechnology & Genome ETF's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wells Fargo & Company MN (1.98%), Royal Bank of Canada (1.41%), LPL Financial LLC (1.34%), CreativeOne Wealth LLC (0.72%), YHB Investment Advisors Inc. (0.58%) and Stifel Financial Corp (0.46%).

How do I buy shares of Invesco Biotechnology & Genome ETF?

Shares of PBE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Invesco Biotechnology & Genome ETF's stock price today?

One share of PBE stock can currently be purchased for approximately $58.48.

How much money does Invesco Biotechnology & Genome ETF make?

Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) has a market capitalization of $232.16 million.

How can I contact Invesco Biotechnology & Genome ETF?

Invesco Biotechnology & Genome ETF's mailing address is 301 West Roosevelt Road, WHEATON, IL 60187, United States. The official website for the company is www.invescopowershares.com. The company can be reached via phone at +1-800-9830903.

This page (NYSEARCA:PBE) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -